180 related articles for article (PubMed ID: 21354955)
21. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
[TBL] [Abstract][Full Text] [Related]
22. Overview and Current Status of Peptide Receptor Radionuclide Therapy.
Bushnell DL; Bodeker KL
Surg Oncol Clin N Am; 2020 Apr; 29(2):317-326. PubMed ID: 32151363
[TBL] [Abstract][Full Text] [Related]
23. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
Graf F; Fahrer J; Maus S; Morgenstern A; Bruchertseifer F; Venkatachalam S; Fottner C; Weber MM; Huelsenbeck J; Schreckenberger M; Kaina B; Miederer M
PLoS One; 2014; 9(2):e88239. PubMed ID: 24516620
[TBL] [Abstract][Full Text] [Related]
24. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable.
Barber TW; Hofman MS; Thomson BN; Hicks RJ
Eur J Surg Oncol; 2012 Jan; 38(1):64-71. PubMed ID: 21906907
[TBL] [Abstract][Full Text] [Related]
25. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.
Smith MC; Liu J; Chen T; Schran H; Yeh CM; Jamar F; Valkema R; Bakker W; Kvols L; Krenning E; Pauwels S
Digestion; 2000; 62 Suppl 1():69-72. PubMed ID: 10940690
[TBL] [Abstract][Full Text] [Related]
26. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.
Kwekkeboom DJ; Krenning EP; Lebtahi R; Komminoth P; Kos-Kudła B; de Herder WW; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):220-6. PubMed ID: 19713714
[TBL] [Abstract][Full Text] [Related]
27. 68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs.
Werner RA; Bluemel C; Allen-Auerbach MS; Higuchi T; Herrmann K
Ann Nucl Med; 2015 Jan; 29(1):1-7. PubMed ID: 25139472
[TBL] [Abstract][Full Text] [Related]
28. Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not?
Yilmaz E; Engin MN; Özkan ZG; Kovan B; Büyükkaya F; Poyanli A; Sağlam S; Başaran M; Türkmen C
Nucl Med Commun; 2020 Dec; 41(12):1242-1249. PubMed ID: 32941405
[TBL] [Abstract][Full Text] [Related]
29. Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review.
Stolniceanu CR; Nistor I; Bilha SC; Constantin V; Simona V; Matovic M; Stefanescu C; Covic A
Nucl Med Commun; 2020 Jul; 41(7):601-617. PubMed ID: 32404645
[TBL] [Abstract][Full Text] [Related]
30. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
31. Neuroendocrine tumor theranostics.
Ichikawa Y; Kobayashi N; Takano S; Kato I; Endo K; Inoue T
Cancer Sci; 2022 Jun; 113(6):1930-1938. PubMed ID: 35271754
[TBL] [Abstract][Full Text] [Related]
32. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
[TBL] [Abstract][Full Text] [Related]
33. Therapy: Neuroendocrine cancer--are two radionuclides better than one?
Kwekkeboom DJ
Nat Rev Endocrinol; 2012 May; 8(6):326-8. PubMed ID: 22547261
[No Abstract] [Full Text] [Related]
34. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.
Bodei L; Cremonesi M; Kidd M; Grana CM; Severi S; Modlin IM; Paganelli G
Thorac Surg Clin; 2014 Aug; 24(3):333-49. PubMed ID: 25065935
[TBL] [Abstract][Full Text] [Related]
35. Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy.
van Schaik E; van Vliet EI; Feelders RA; Krenning EP; Khan S; Kamp K; Valkema R; van Nederveen FH; Teunissen JJ; Kwekkeboom DJ; de Herder WW
J Clin Endocrinol Metab; 2011 Nov; 96(11):3381-9. PubMed ID: 21917872
[TBL] [Abstract][Full Text] [Related]
36. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin and somatostatin receptors: from basic concepts to clinical applications.
De Martino MC; Hofland LJ; Lamberts SW
Prog Brain Res; 2010; 182():255-80. PubMed ID: 20541669
[TBL] [Abstract][Full Text] [Related]
38. Lutetium-177 Labeled Peptides: The European Institute of Oncology Experience.
Carollo A; Papi S; Chinol M
Curr Radiopharm; 2016; 9(1):19-32. PubMed ID: 25771368
[TBL] [Abstract][Full Text] [Related]
39. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors.
Wang L; Tang K; Zhang Q; Li H; Wen Z; Zhang H; Zhang H
Biomed Res Int; 2013; 2013():102819. PubMed ID: 24106690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
